EUVIMEDEUVIMED entdecken
Crossref

Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?

Yu-Ching Kuo, Mei Hsiu-Ching Ho

Tulane Journal of Technology & Intellectual Property · 08.06.2023 · 24

DOI: 10.37381/ersdsb53 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Tulane Journal of Technology & Intellectual Property, online erschienen am 08.06.2023. Verfasst von Yu-Ching Kuo und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This research explores biopharmaceutical companies’ behavior of obtaining patentprotection under the tightened patentability standard for biotechnology innovation. To explore theimportance of innovations, we collected time-series data from twenty firms over two decades andexamined the role of biotechnology on a firm’s operating performance and profit via an empiricalregression model. The results suggest that greater R&D investment brings firms higher revenue andprofit, but a more influential patent does not seem to reward all companies. The possession ofbiotechnology can help companies increase revenue. For large-scale R&D firms, marketinginvolvement is particularly important to boost revenue, but low-scale R&D firms should avoidhaving a high ratio of biotechnology in their patent portfolio strategy.

Zitieren

APA

Kuo, Y., & Ho, M. H. (2023). Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?. Tulane Journal of Technology & Intellectual Property, 24. https://doi.org/10.37381/ersdsb53

Vancouver

Kuo Y, Ho MH. Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?. Tulane Journal of Technology & Intellectual Property. 2023;24. doi:10.37381/ersdsb53

BibTeX
@article{Kuo2023,
  author = {Kuo, Yu-Ching and Ho, Mei Hsiu-Ching},
  title = {Gene Patents: Incentive or Impediment for Pharmaceutical Innovation?},
  journal = {Tulane Journal of Technology & Intellectual Property},
  year = {2023},
  volume = {24},
  doi = {10.37381/ersdsb53}
}
Kostenlos starten →